Incidence and Survival Trends of Pancreatic Cancer in Girona: Impact of the Change in Patient Care in the Last 25 Years

Adelaida García-Velasco, Lluís Zacarías-Pons, Helena Teixidor, Marc Valeros, Raquel Liñan, M. Carmen Carmona-Garcia, Montse Puigdemont, Walter Carbajal, Raquel Guardeño, Núria Malats, Eric Duell and Rafael Marcos-Gragera
Additional contact information
Adelaida García-Velasco: Medical Oncology Department, Josep Trueta Universitary Hospital, Catalan Institute of Oncology, Av de França, 17007 Girona, Spain
Lluís Zacarías-Pons: Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Av. França, s/n, 17004 Girona, Spain
Helena Teixidor: Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Av. França, s/n, 17004 Girona, Spain
Marc Valeros: Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Av. França, s/n, 17004 Girona, Spain
Raquel Liñan: Medical Oncology Department, Josep Trueta Universitary Hospital, Catalan Institute of Oncology, Av de França, 17007 Girona, Spain
M. Carmen Carmona-Garcia: Medical Oncology Department, Josep Trueta Universitary Hospital, Catalan Institute of Oncology, Av de França, 17007 Girona, Spain
Montse Puigdemont: Descriptive Epidemiology, Genetics and Cancer Prevention Group, Biomedical Research Institute (IDIBGI), C/Dr. Castany, s/n, 17190 Salt, Spain
Walter Carbajal: Medical Oncology Department, Josep Trueta Universitary Hospital, Catalan Institute of Oncology, Av de França, 17007 Girona, Spain
Raquel Guardeño: Medical Oncology Department, Josep Trueta Universitary Hospital, Catalan Institute of Oncology, Av de França, 17007 Girona, Spain
Núria Malats: Genetic and Molecular Epidemiology Group, Spanish National Cancer Research (CNIO) and CIBERONC, 28029 Madrid, Spain
Eric Duell: Unit of Biomarkers and Susceptibility, Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), Colorectal Cancer Group, ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 08908 Barcelona, Spain
Rafael Marcos-Gragera: Descriptive Epidemiology, Genetics and Cancer Prevention Group, Biomedical Research Institute (IDIBGI), C/Dr. Castany, s/n, 17190 Salt, Spain

IJERPH, 2020, vol. 17, issue 24, 1-22

Abstract: (1) Background: We investigated the incidence and survival trends for pancreatic cancer (PC) over the last 25 years in the Girona region, Catalonia, Spain; (2) Methods: Data were extracted from the population-based Girona Cancer Registry. Incident PC cases during 1994–2015 were classified using the International Classification of Diseases for Oncology Third Edition (ICD-O-3). Incidence rates age-adjusted to the European standard population (ASR E ) and world standard population (ASR W ) were obtained. Trends were assessed using the estimated annual percentage of change (EAPC) of the ASR E13. Observed and relative survivals (RS) were estimated with the Kaplan–Meier and Pohar Perme methods, respectively; (3) Results: We identified 1602 PC incident cases. According to histology, 44.4% of cases were exocrine PC, 4.1% neuroendocrine, and 51.1% malignant-non-specified. The crude incidence rate (CR) for PC was 11.43 cases-per-100,000 inhabitants/year. A significant increase of incidence with age and over the study period was observed. PC overall 5-year RS was 7.05% (95% confidence interval (CI) 5.63; 8.84). Longer overall survival was observed in patients with neuroendocrine tumours (5-year RS 61.45%; 95% CI 47.47; 79.55). Trends in 5-year RS for the whole cohort rose from 3.27% (95% CI 1.69–6.35) in 1994–1998 to 13.1% (95% CI 9.98; 17.2) in 2010–2015; (4) Conclusions: Incidence rates of PC in Girona have increased in the last two decades. There is a moderate but encouraging increase in survival thorough the study period. These results can be used as baseline for future research.

Keywords: pancreatic cancer; incidence; relative survival; pancreatic neuroendocrine tumours (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2020
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.mdpi.com/1660-4601/17/24/9538/pdf (application/pdf)
https://www.mdpi.com/1660-4601/17/24/9538/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:17:y:2020:i:24:p:9538-:d:465214

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().